Literature DB >> 22820187

Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma.

Dingxie Liu1, Xuan Liu, Mingzhao Xing.   

Abstract

We have previously reported that the BRAFV600E signaling causes genome-wide aberrations in gene methylation in melanoma cells. To explore the potential molecular mechanisms for this epigenetic effect of BRAFV600E, in this in silico study we analyzed 11 microarray datasets retrieved from NCBI GEO database and examined the relationship of the expression of the epigenetic genes (genes involved in epigenetic regulation) with BRAFV600E signaling, methylation and expression of tumor-suppressor genes (TSGs) in melanoma, and patient survival with this cancer. Among 273 epigenetic genes examined, 12 genes were down-regulated (named DD genes) and 16 were up-regulated (UU genes) by suppression of the BRAFV600E signaling using inhibitors. While the expression of 245 non-DD/UU genes overall had no correlation with the expression and methylation of a set of potential TSGs, the expression of DD genes was significantly correlated negatively with the TSG expression and positively with TSG methylation. Expression of UU genes was positively, albeit weakly, associated with the TSG expression. Overall, no correlation was found between UU gene expression and TSG methylation. Importantly, the expression of DD genes, but not UU genes, was significantly associated with decreased survival of patients with melanoma. Interestingly, the promoters of DD genes contain more binding motifs of c-fos and myc, two BRAFV600E signaling-related transcription factors, than those of UU and non-DD/UU genes. Thus, these results link epigenetic genes to methylation and suppression of tumor suppressor genes as a mechanism involved in BRAFV600E-promoted melanoma tumorigenesis and uncover a novel molecular signature that predicts a poor prognosis of melanoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820187      PMCID: PMC3454505          DOI: 10.1016/j.bbrc.2012.07.046

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  Melanoma.

Authors:  Arlo J Miller; Martin C Mihm
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 2.  Mechanisms of drug inhibition of signalling molecules.

Authors:  Judith S Sebolt-Leopold; Jessie M English
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

Authors:  Göran Jönsson; Christian Busch; Stian Knappskog; Jürgen Geisler; Hrvoje Miletic; Markus Ringnér; Johan R Lillehaug; Ake Borg; Per Eystein Lønning
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

5.  PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing.

Authors:  Quan Zhao; Gerhard Rank; Yuen T Tan; Haitao Li; Robert L Moritz; Richard J Simpson; Loretta Cerruti; David J Curtis; Dinshaw J Patel; C David Allis; John M Cunningham; Stephen M Jane
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

6.  Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins.

Authors:  Vincent Verbiest; Danièle Montaudon; Michel T Tautu; Joyce Moukarzel; Jean-Pierre Portail; Judith Markovits; Jacques Robert; François Ichas; Philippe Pourquier
Journal:  FEBS Lett       Date:  2008-03-31       Impact factor: 4.124

7.  Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells.

Authors:  Pierre-Olivier Estève; Hang Gyeong Chin; Jack Benner; George R Feehery; Mala Samaranayake; Gregory A Horwitz; Steven E Jacobsen; Sriharsa Pradhan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

8.  Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor.

Authors:  Xiaojin An; Yi Jin; Hongnian Guo; Shi-Yin Foo; Brittany L Cully; Jiaping Wu; Huiyan Zeng; Anthony Rosenzweig; Jian Li
Journal:  Circulation       Date:  2009-08-03       Impact factor: 29.690

Review 9.  Protein arginine methylation in mammals: who, what, and why.

Authors:  Mark T Bedford; Steven G Clarke
Journal:  Mol Cell       Date:  2009-01-16       Impact factor: 17.970

10.  (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Authors:  Christine A Pratilas; Barry S Taylor; Qing Ye; Agnes Viale; Chris Sander; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

View more
  6 in total

1.  Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

2.  DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features.

Authors:  Nancy E Thomas; Nathaniel A Slater; Sharon N Edmiston; Xin Zhou; Pei-Fen Kuan; Pamela A Groben; Craig C Carson; Honglin Hao; Eloise Parrish; Stergios J Moschos; Marianne Berwick; David W Ollila; Kathleen Conway
Journal:  Pigment Cell Melanoma Res       Date:  2014-07-14       Impact factor: 4.693

3.  Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.

Authors:  Dingxie Liu; Jonathan Benzaquen; Luc G T Morris; Marius Ilié; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

4.  Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.

Authors:  Wei Jiang; Peilin Jia; Katherine E Hutchinson; Douglas B Johnson; Jeffrey A Sosman; Zhongming Zhao
Journal:  Oncotarget       Date:  2015-02-10

5.  REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.

Authors:  Dingxie Liu; Xiaopei Shen; Guangwu Zhu; Mingzhao Xing
Journal:  Oncotarget       Date:  2015-11-17

6.  DNA methylation characteristics of primary melanomas with distinct biological behaviour.

Authors:  Szilvia Ecsedi; Hector Hernandez-Vargas; Sheila C Lima; Laura Vizkeleti; Reka Toth; Viktoria Lazar; Viktoria Koroknai; Timea Kiss; Gabriella Emri; Zdenko Herceg; Roza Adany; Margit Balazs
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.